Attenuation of HbA1 creduction was not edin both study arms at 104 weeks;however,the gradual increase in HbA1c over time was less profound with dapagliflozin than with glipizide. At week 208, dapagliflozin was associated with a reduced HbA1c concentration compared with glipizide (−0.10 vs 0.20%, respectively). This emphasized the between-group differences in HbA1c reduction during the extension periods [week 104,
−0.18% (95% CI −0.33, −0.03); week 208, −0.30% (95% CI −0.51, −0.09), Figure 1A]. Subgroup analyses showed similar patterns in HbA1c reduction, with greater effects as baseline HbA1c levels increased.To account for patient attri tionin this long-term trial, longitudinal repeated measures analyses that included data after rescue were conducted and showed similar patterns of HbA1 creduction.